Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for treating gefitinib resistant cancer

一种吉非替尼、耐药性的技术，应用在治疗吉非替尼耐药性癌症领域

Pending Publication Date: 2018-08-21
THE GENERAL HOSPITAL CORP +1
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] A significant limitation in the use of these compounds is that their recipients may develop resistance to their therapeutic effects after an initial response to therapy, or they may not respond to EGFR-TKIs at any detectable level

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating gefitinib resistant cancer
  • Method for treating gefitinib resistant cancer
  • Method for treating gefitinib resistant cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0079] compound. Compounds used herein, including EKB-569, HKI-357, and HKI-272 as described in: U.S. Patent No. 6,002,008; Greenberger et al., Proc. 11 th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Clinical. Cancer Res. Vol. 6 Supplement, Nov. 2000, ISSN 1078-0432; Rabindran et al., Cancer Res. 64:3958-3965 (2004); Holbro and Hynes, Ann. Rev. Pharm. Tox. 44: 195-217 (2004); and Tejpar et al., J. Clin. Oncol. ASCO Annual Meeting Proc. Vol. 22, No. 14S: 3579 (2004).

[0080]Analysis of relapsed NSCLC and generation of gefitinib-resistant NCI-H1 650 cells. After obtaining appropriate consent, autopsies were performed to obtain clinical samples of recurrent NSCLC. Following analysis of non-clonal PCR products, the entire kinase domain of EGFR was sequenced. Multiplex clones of exon 20 were sequenced to detect codon 790. By automated sequencing of single exons using dye terminator chemistry (BIGDYE version 1.1, Applied Biosystems) and flanking intronic (flanking...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to methods for the treatment of gefitinib and / or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and / or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and / or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.

Description

[0001] This application is a divisional application of an invention application with the application date of February 02, 2006, the application number 201210328133.2, and the title "Method for Treating Gefitinib-resistant Cancer"; the application date is February 02, 2006 , the application number is 201210328133.2, and the invention application titled "method for the treatment of gefitinib-resistant cancer" is the application date of February 02, 2006, the application number is 200680011003.9, and the title of the invention is "the treatment of gefitinib-resistant cancer". A divisional application of the invention application of "method for drug-induced cancer". Background of the invention [0002] Epithelial cell carcinomas, eg, prostate, breast, colon, lung, pancreas, ovary, spleen, testis, thymus, etc., are diseases characterized by abnormal accelerated growth of epithelial cells. This accelerated growth initially causes tumor formation. Finally, metastases to different or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/5377A61K31/517A61K31/4709A61K31/4706A61P35/00
CPCA61K31/4706A61K38/17A61P35/00A61P43/00A61K31/4709A61K35/00
Inventor D·哈伯D·W·贝尔J·E·塞特尔曼R·索尔德拉N·G·戈丁-海曼E·L·夸克S·K·拉宾兰
Owner THE GENERAL HOSPITAL CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com